# A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

> **NCT01389973** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 20 (actual)

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **DRUG:** ustekinumab 90 mg
- **DRUG:** ustekinumab 45 mg
- **DRUG:** ustekinumab 180 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01389973
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01389973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01389973, "A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01389973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*